|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.2361 - 5.3500|
|52 Week Range||3.0000 - 14.0000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced that it would be entering the convenience store market segment through an agreement with E&S International Enterprises, Inc. (“ESI”), for the distribution of CBDMEDIC™ products to this channel. ESI has a strong presence in the convenience store channel based on its leadership in the wholesale and distribution of consumer products. Abacus has developed new form factors of its leading topical pain relief and skincare product line, CBDMEDIC, as well as unique presentation platforms, specifically designed for the convenience store market.
Abacus Health Products, Inc. (CSE: ABCS, OTCQX:ABAHF) (“Abacus” or the “Company”) today announced that it will participate in two industry conferences: The Eight Capital & Cassels Brock Global Cannabis Conference being held on September 19, 2019 at The Shangri-La Hotel in Toronto and the Alliance Global Partners’ Consumer Cannabis Conference to be held on October 3, 2019 at The Pierre Hotel in New York City. Abacus will participate in panel discussions at both conferences to discuss the rapidly growing CBD industry and will also be available for 1x1 meetings. This news release contains forward-looking statements or information (collectively, “forward-looking statements”) within the meaning of applicable securities legislation.
NEW YORK, Aug. 27, 2019 /PRNewswire/ -- Rob Gronkowski, three-time professional football champion with several records to his name, today announced that he has become an advocate for CBD and an investor in Abacus Health Products (ABCS.CN)(ABAHF) ("Abacus" or the "Company"). Abacus is the maker of CBDMEDIC, the first family of all-natural topical medications that combine over the counter (OTC) drug active ingredients with CBD-rich hemp oil and other natural moisturizers.
WOONSOCKET, RI and TORONTO , July 31, 2019 /CNW/ - Abacus Health Products, Inc. ("Abacus" or the "Company") (CSE: ABCS) (ABAHF) is pleased to announce that Mr. Hannan Fleiman has joined its board of directors. Mr. Fleiman will also serve as Chair of the Company's Audit Committee and Corporate Governance, Nominating and Compensation Committee. With the addition of Mr. Fleiman, Abacus now has a total of five directors on its board. "I am pleased to welcome Hannan Fleiman to Abacus' board of directors," said Perry Antelman , CEO of Abacus.
WOONSOCKET, RI , July 2, 2019 /CNW/ - Abacus Health Products, Inc. ("Abacus" or the "Company") (CSE: ABCS) (ABAHF) today announced its subordinate voting shares have begun trading on the OTCQX Market under the symbol "ABAHF" effective July 1, 2019 . "Having a dual listing on both the OTCQX and the CSE has been an important objective for our company," said Perry Antelman , CEO. This news release contains forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities legislation.
NEW YORK , July 1, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Abacus Health Products Inc (CSE: ABCS; ...
TORONTO , May 30, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") reported its financial results today for the first quarter ended March 31, 2019 . CBD CLINIC continued to perform well with revenue increasing 148% YoY, from $1,433,243 to $3,553,751 , and an increase of 23% over the fourth quarter of 2018, from $2,886,412 . Purchase orders received to date represent over 2,000 retail pharmacy and supermarket locations across 11 states.
WOONSOCKET, RI and TORONTO, May 23, 2019 /PRNewswire/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced that renowned Hollywood fitness trainer and nutritional expert, Harley Pasternak, will be working with the Company to increase public awareness of its CBDMEDIC™ line of pain relief and skincare products. Pasternak holds a Master of Science in Exercise Physiology and Nutritional Sciences from the University of Toronto and an Honors Degree in Kinesiology from the University of Western Ontario.
Abacus Health Products Announces Release Date, Conference Call and Webcast Details for 2019 First Quarter Financial Results
WOONSOCKET, RI and TORONTO, May 10, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced further growth in the distribution and availability of their line of CBDMEDIC™ products. "These purchase orders, which range from six to twelve unique SKUs across our pain relief and therapeutic skincare lines, demonstrate the continued strong interest by retail chains to bring CBDMEDIC™ products onto their shelves," said Perry Antelman , CEO of Abacus. Further, a 2018 research report by Allied Market Research estimated the global topical pain relief market to be approximately US$7.4 billion in 2017.
TORONTO , Feb. 28, 2019 /CNW/ - Abacus Health Products, Inc. (CSE:ABCS) ("Abacus" or the "Company") today announced its first purchase order received from a major United States retail chain. "This purchase order marks an important milestone in our growth strategy of securing major US retail chains to distribute our products," said Perry Antelman , CEO of Abacus. Abacus has developed a range of innovative products based on patent-pending technologies which combine natural and organic ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant.